[1] CHO N, SHAW J, KARURANGA S, et al. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045[J]. DIABETES RES CLIN PR, 2018, 138:271-281. doi:  10.1016/j.diabres.2018.02.023
[2] MARTÍNEZ-CASTELAO A, NAVARRO-GONZÁLEZ J, GÓRRIZ J, et al. The concept and the epidemiology of diabetic nephropathy have changed in recent years[J]. J Clin Med, 2015, 4(6):1207-1216. doi:  10.3390/jcm4061207
[3] SARAN R, ROBINSON B, ABBOTT K C, et al. US renal data system 2016 annual data report: epidemiology of kidney disease in the United States[J]. Am J Kidney Dis, 2017, 69(3):A4. doi:  10.1053/j.ajkd.2017.01.036
[4] VALENCIA WM, FLOREZ H.How to prevent the microvascular complications of type 2 diabetes beyond glucose control[J]. BMJ, 2017, 356: j1018.
[5] CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC). Incidence of end-stage renal disease attributed to diabetes among persons with diagnosed diabetes: - United States and Puerto Rico, 1996-2007[J]. MMWR Morb Mortal Wkly Rep, 2010, 59(42):1361-1366.
[6] ZHANG L X, LONG J Y, JIANG W S, et al. Trends in chronic kidney disease in China[J]. N Engl J Med, 2016, 375(9):905-906. doi:  10.1056/NEJMc1602469
[7] OSAMA G, NASHWA F, NARAYANAN N, et al. Diabetic kidney disease: world wide difference of prevalence and risk factors[J]. J Nephropharmacology, 2016, 5(1):49-56.
[8] STENVINKEL P. Chronic kidney disease: a public health priority and harbinger of premature cardiovascular disease[J]. Journal of internal medicine 2010; 268: 456-467.
[9] IATCU C O, STEEN A, COVASA M. Gut microbiota and complications of type-2 diabetes[J]. Nutrients, 2021, 14(1):166. doi:  10.3390/nu14010166
[10] WILSON TANG W H, KITAI T, HAZEN S L. Gut microbiota in cardiovascular health and disease[J]. Circ Res, 2017, 120(7):1183-1196. doi:  10.1161/CIRCRESAHA.117.309715
[11] SCHROEDER B O, BÄCKHED F. Signals from the gut microbiota to distant organs in physiology and disease[J]. Nat Med, 2016, 22(10):1079-1089. doi:  10.1038/nm.4185
[12] YANG G, WEI J, LIU P, et al. Role of the gut microbiota in type 2 diabetes and related diseases[J]. METABOLISM, 2021, 117:154712. doi:  10.1016/j.metabol.2021.154712
[13] SHARMA M, LI Y Y, STOLL M L, et al. The epigenetic connection between the gut microbiome in obesity and diabetes[J]. Front Genet, 2020, 10:1329. doi:  10.3389/fgene.2019.01329
[14] JAWORSKA K, KOPACZ W, KOPER M, et al. Enalapril diminishes the diabetes-induced changes in intestinal morphology, intestinal RAS and blood SCFA concentration in rats[J]. Int J Mol Sci, 2022, 23(11):6060. doi:  10.3390/ijms23116060
[15] DU X, LIU J, XUE Y, et al. Alteration of gut microbial profile in patients with diabetic nephropathy[J]. Endocrine, 2021, 73(1):71-84. doi:  10.1007/s12020-021-02721-1
[16] QIN J J, LI Y R, CAI Z M, et al. A metagenome-wide association study of gut microbiota in type 2 diabetes[J]. Nature, 2012, 490(7418):55-60. doi:  10.1038/nature11450
[17] KARLSSON F H, TREMAROLI V, NOOKAEW I, et al. Gut metagenome in European women with normal, impaired and diabetic glucose control[J]. Nature, 2013, 498(7452):99-103. doi:  10.1038/nature12198
[18] ZHANG L, LU Q Y, WU H, et al. The intestinal microbiota composition in early and late stages of diabetic kidney disease[J]. Microbiol Spectr, 2023, 11(4):e0038223. doi:  10.1128/spectrum.00382-23
[19] KALANTAR-ZADEH K, JAFAR T H, NITSCH D, et al. Chronic kidney disease[J]. Lancet, 2021, 398(10302):786-802. doi:  10.1016/S0140-6736(21)00519-5
[20] WANG X, YANG S, LI S, et al. Aberrant gut microbiota alters host metabolome and impacts renal failure in humans and rodents[J]. Gut, 2020, 69(12):2131-2142. doi:  10.1136/gutjnl-2019-319766
[21] WANG S L, SHAO B Z, ZHAO S B, et al. Impact of paneth cell autophagy on inflammatory bowel disease[J]. Front Immunol, 2018, 9:693. doi:  10.3389/fimmu.2018.00693
[22] BUCKLEY A, TURNER J R. Cell biology of tight junction barrier regulation and mucosal disease[J]. Cold Spring Harb Perspect Biol, 2018, 10(1):a029314. doi:  10.1101/cshperspect.a029314
[23] MAHMOODPOOR F, RAHBAR SAADAT Y, BARZEGARI A, et al. The impact of gut microbiota on kidney function and pathogenesis[J]. Biomed Pharmacother, 2017, 93:412-419. doi:  10.1016/j.biopha.2017.06.066
[24] VAZIRI N D, YUAN J, NORRIS K. Role of urea in intestinal barrier dysfunction and disruption of epithelial tight junction in chronic kidney disease[J]. Am J Nephrol, 2013, 37(1):1-6. doi:  10.1159/000345969
[25] MATHEWSON N D, JENQ R, MATHEW A V, et al. Gut microbiome-derived metabolites modulate intestinal epithelial cell damage and mitigate graft-versus-host disease[J]. Nat Immunol, 2016, 17(5):505-513. doi:  10.1038/ni.3400
[26] HUANG X Y, OSHIMA T, TOMITA T, et al. Butyrate alleviates cytokine-induced barrier dysfunction by modifying claudin-2 levels[J]. Biology, 2021, 10(3):205. doi:  10.3390/biology10030205
[27] NOWARSKI R, JACKSON R, GAGLIANI N, et al. Epithelial IL-18 equilibrium controls barrier function in colitis[J]. Cell, 2015, 163(6):1444-1456. doi:  10.1016/j.cell.2015.10.072
[28] TONG L C, WANG Y, WANG Z B, et al. Propionate ameliorates dextran sodium sulfate-induced colitis by improving intestinal barrier function and reducing inflammation and oxidative stress[J]. Front Pharmacol, 2016, 7:253.
[29] FENG Y H, WANG Y, WANG P, et al. Short-chain fatty acids manifest stimulative and protective effects on intestinal barrier function through the inhibition of NLRP3 inflammasome and autophagy[J]. Cell Physiol Biochem, 2018, 49(1):190-205. doi:  10.1159/000492853
[30] SAYIN S, WAHLSTRÖM A, FELIN J, et al. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist[J]. Cell Metab, 2013, 17(2):225-235. doi:  10.1016/j.cmet.2013.01.003
[31] SCHAAP F G, TRAUNER M, JANSEN P L M. Bile acid receptors as targets for drug development[J]. Nat Rev Gastroenterol Hepatol, 2014, 11(1):55-67. doi:  10.1038/nrgastro.2013.151
[32] HUANG W D, MA K, ZHANG J, et al. Nuclear receptor-dependent bile acid signaling is required for normal liver regeneration[J]. Science, 2006, 312(5771):233-236. doi:  10.1126/science.1121435
[33] WANG X X, WANG D, LUO Y H, et al. FXR/TGR5 dual agonist prevents progression of nephropathy in diabetes and obesity[J]. J Am Soc Nephrol, 2018, 29(1):118-137. doi:  10.1681/ASN.2017020222
[34] XIAO H M, SUN X H, LIU R B, et al. Gentiopicroside activates the bile acid receptor Gpbar1 (TGR5) to repress NF-kappaB pathway and ameliorate diabetic nephropathy[J]. Pharmacol Res, 2020, 151:104559. doi:  10.1016/j.phrs.2019.104559
[35] MARQUARDT A, AL-DABET M M, GHOSH S, et al. Farnesoid X receptor agonism protects against diabetic tubulopathy: potential add-on therapy for diabetic nephropathy[J]. J Am Soc Nephrol, 2017, 28(11):3182-3189. doi:  10.1681/ASN.2016101123
[36] DU Y, YANG Y T, TANG G, et al. Butyrate alleviates diabetic kidney disease by mediating the miR-7a-5p/P311/TGF-β1 pathway[J]. FASEB J, 2020, 34(8):10462-10475. doi:  10.1096/fj.202000431R
[37] DONG W P, JIA Y, LIU X X, et al. Sodium butyrate activates NRF2 to ameliorate diabetic nephropathy possibly via inhibition of HDAC[J]. J Endocrinol, 2017, 232(1):71-83. doi:  10.1530/JOE-16-0322
[38] XU Y H, GAO C L, GUO H L, et al. Sodium butyrate supplementation ameliorates diabetic inflammation in db/db mice[J]. J Endocrinol, 2018, 238(3): 231-244.
[39] RAMEZANI A, MASSY Z A, MEIJERS B, et al. Role of the gut microbiome in uremia: a potential therapeutic target[J]. Am J Kidney Dis, 2016, 67(3):483-498.
[40] ZHANG F, QI L L, FENG Q Y, et al. HIPK2 phosphorylates HDAC3 for NF-κB acetylation to ameliorate colitis-associated colorectal carcinoma and sepsis[J]. Proc Natl Acad Sci USA, 2021, 118(28):e2021798118. doi:  10.1073/pnas.2021798118
[41] HU X Y, LI S M, FU Y H, et al. Targeting gut microbiota as a possible therapy for mastitis[J]. Eur J Clin Microbiol Infect Dis, 2019, 38(8):1409-1423. doi:  10.1007/s10096-019-03549-4
[42] HU Z B, LU J, CHEN P P, et al. Dysbiosis of intestinal microbiota mediates tubulointerstitial injury in diabetic nephropathy via the disruption of cholesterol homeostasis[J]. Theranostics, 2020, 10(6):2803-2816. doi:  10.7150/thno.40571
[43] LU C C, HU Z B, WANG R, et al. Gut microbiota dysbiosis-induced activation of the intrarenal renin-angiotensin system is involved in kidney injuries in rat diabetic nephropathy[J]. Acta Pharmacol Sin, 2020, 41(8):1111-1118. doi:  10.1038/s41401-019-0326-5
[44] GRUPPEN E G, GARCIA E, CONNELLY M A, et al. TMAO is associated with mortality: impact of modestly impaired renal function[J]. Sci Rep, 2017, 7(1):13781. doi:  10.1038/s41598-017-13739-9
[45] SUN G P, YIN Z M, LIU N Q, et al. Gut microbial metabolite TMAO contributes to renal dysfunction in a mouse model of diet-induced obesity[J]. Biochem Biophys Res Commun, 2017, 493(2):964-970. doi:  10.1016/j.bbrc.2017.09.108
[46] AL-OBAIDE M, SINGH R, DATTA P, et al. Gut microbiota-dependent trimethylamine-N-oxide and serum biomarkers in patients with T2DM and advanced CKD[J]. J Clin Med, 2017, 6(9):86. doi:  10.3390/jcm6090086
[47] YANG M X, ZHANG R, ZHUANG C F, et al. Serum trimethylamine N-oxide and the diversity of the intestinal microbial flora in type 2 diabetes complicated by diabetic kidney disease[J]. Clin Lab, 2022, 68(5): 10.7754/Clin. Lab. 2021.210836.
[48] FANG Q, ZHENG B J, LIU N, et al. Trimethylamine N-oxide exacerbates renal inflammation and fibrosis in rats with diabetic kidney disease[J]. Front Physiol, 2021, 12:682482. doi:  10.3389/fphys.2021.682482
[49] MAO Z H, GAO Z X, LIU D W, et al. Gut microbiota and its metabolites–molecular mechanisms and management strategies in diabetic kidney disease[J]. Front Immunol, 2023, 14:1124704. doi:  10.3389/fimmu.2023.1124704